Loading organizations...
Loading organizations...
1st Biotherapeutics: Clinical-stage biotech firm developing small molecule drugs for neurodegenerative, immuno-oncology, and rare diseases.
1st Biotherapeutics is a clinical-stage biotechnology company based in Gyeonggi Province, South Korea, that discovers and develops novel small molecule therapeutics for neurodegenerative conditions, immuno-oncology, and rare diseases. The pre-revenue firm operates with an estimated 10 to 50 employees and utilizes genomic-based target discovery platforms to advance its clinical pipeline. To date, the enterprise has raised approximately $60 million in total venture funding, which includes a $24 million Series D round completed in January 2026. Its financial backing comes from a syndicate of institutional investors featuring Korea Investment Partners, Smilegate Investment, and DSC Investment. The company also maintains strategic research collaborations with industry partners such as Neuraly and LigaChem Biosciences to co-develop brain-penetrant inhibitors and out-license drug candidates. 1st Biotherapeutics was founded in 2016 by Jae Eun Kim.
1st Biotherapeutics has raised $22.0M across 1 funding round.
1st Biotherapeutics has raised $22.0M in total across 1 funding round.
1st Biotherapeutics has raised $22.0M in total across 1 funding round.
1st Biotherapeutics has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series D in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 27, 2026 | $22.0M Series D |